Kura Oncology Inc (KURA) Q3 2024 Earnings Report

- QQ3 2024 (quarter ended 2024-09-30) was an R&D-intensive period for Kura Oncology, with no revenue and a reported net loss of $54.4 million ($0.63 per basic and diluted share) as the company advanced its early-stage oncology programs. R&D expenses rose to $41.7 million from $29.3 million a year ago, while G&A expenses climbed to $18.2 million from $13.1 million, reflecting expanded clinical activity and organizational investments. The company ended Q3 2024 with cash, cash equivalents and short-term investments of $455.3 million (cash of $49.48 million on the balance sheet; total cash and investments $455.3 million), providing management with a stated runway into 2027.
- On the operating front, Kura reported an EBITDA loss of $59.7 million and a net operating loss of $59.9 million for the quarter. The cash burn was driven by ziftomenib and KO-2806 program costs, with management emphasizing the intent to sustain the operating plan into 2027. Importantly, management framed a multi-year value-building path driven by KOMET-007 (ziftomenib in combination with ven/aza and 7+3), KOMET-001 (NPM1-mutant relapsed/refractory AML) topline in early 2025, and a robust development roadmap across several programs including GIST and diabetes initiatives via next-generation menin inhibitors.
- Management commentary underscored a strategic shift toward frontline opportunity in addition to relapsed/refractory AML, with early signals suggesting durable activity and a favorable tolerability profile at higher dose levels (600 mg RP2D) supporting expansion cohorts. The company also highlighted potential MRD-based endpoints as upside opportunities in frontline studies, subject to regulatory acceptance. The near-term milestones include ASH data in December 2024, top-line KOMET-001 results in early 2025, and an anticipated pivotal program initiation in mid-2025, with an NDA submission target in the latter half of 2025 pending data outcomes and regulatory alignment.